- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00369850
Bone Density and Bone Loss in Postmenopausal Women With Breast Cancer Receiving Treatment in Clinical Trial IBCSG-1-98
Investigating Bone Density and Bone Loss Without Baseline Information
RATIONALE: Diagnostic procedures, such as bone mineral density testing and x-ray, help measure bone loss in women receiving treatment for breast cancer. The test results may help doctors plan better treatment.
PURPOSE: This phase III trial is studying bone density and bone loss in postmenopausal women with breast cancer receiving treatment in clinical trial IBCSG-1-98.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
OBJECTIVES:
- Compare the effects on bone mineral density (BMD) in the L2-L4 (posterio-anterior) region of the spine and hip by assessing bone density in postmenopausal women with breast cancer receiving treatment on protocol IBCSG-1-98.
- Compare the incidence of radiological gross changes and fractures identified from spine x-rays (T4-L4) in these patients (in groups 1 and 2).
- Use longitudinal BMD measurements to estimate a linear rate of bone loss based on mixed effect models.
- Identify serum markers for bone loss to determine how they correlate with osteoporosis, microfractures, clinical fractures, and breast cancer-related bone events.
OUTLINE: This is a multicenter study and a substudy of protocol IBCSG-1-98. Patients are assigned to 1 of 3 groups according to the length of treatment they have undergone on protocol IBCSG-1-98.
- Group 1 (prior to or at the end of the second year of treatment on protocol IBCSG-1-98): Patients undergo bone mineral density (BMD) testing of the L2-L4 spine and hip at baseline and years 1, 2, 3, and 4 from baseline. They also undergo x-rays of the T4-L4 spine at baseline and years 1, 3, and 4 from baseline.
- Group 2 (after 2 years but before the end of the third year of treatment on protocol IBCSG-1-98): Patients undergo BMD testing of the L2-L4 spine and hip at baseline and years 1, 2, and 3 from baseline. They also undergo x-rays of the T4-L4 spine at baseline and years 2 and 3 from baseline.
- Group 3 (after 3 years but before the end of the fifth year of treatment on protocol IBCSG-1-98): Patients undergo BMD testing of the L2-L4 spine and hip at baseline and years 1 and 2 from baseline (for patients in 4th year of treatment) or year 1 from baseline (for patients in 5th year of treatment).
Patients undergo blood collection at baseline and periodically during study for biomarker correlative study.
PROJECTED ACCRUAL: A total of 660 patients will be accrued for this study.
Type d'étude
Inscription (Réel)
Phase
- Phase 3
Contacts et emplacements
Lieux d'étude
-
-
-
Cape Town, Afrique du Sud, 7925
- Groote Schuur Hospital
-
-
-
-
New South Wales
-
Randwick, New South Wales, Australie, 2031
- Institute of Oncology at Prince of Wales Hospital
-
-
Queensland
-
Brisbane, Queensland, Australie, 4029
- Royal Brisbane and Women's Hospital
-
-
-
-
-
Madrid, Espagne, 28034
- Hospital Ruber Internacional
-
-
-
-
-
Bordeaux, France, 33076
- Institut Bergonié
-
-
-
-
-
Aviano, Italie, 33081
- Centro di Riferimento Oncologico - Aviano
-
Bergamo, Italie, 24100
- Ospedali Riuniti di Bergamo
-
Milano, Italie, 20141
- European Institute of Oncology
-
-
-
-
-
Dunedin, Nouvelle-Zélande
- Dunedin Hospital
-
-
-
-
-
Lima, Pérou, 34
- Instituto Nacional de Enfermedades Neoplasicas
-
-
-
-
-
Aarau, Suisse, CH-5001
- Kantonspital Aarau
-
Bern, Suisse, CH-3010
- Inselspital Bern
-
Lausanne, Suisse, CH-1011
- Centre Hospitalier Universitaire Vaudois
-
Mendrisio, Suisse, CH-6850
- Ospedale Beata Vergine
-
St. Gallen, Suisse, CH-9007
- Kantonsspital - St. Gallen
-
Thun, Suisse, 3600
- Regionalspital
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
DISEASE CHARACTERISTICS:
Diagnosis of breast cancer
- Resected disease
Enrolled on protocol IBCSG-1-98
Receiving adjuvant endocrine therapy comprising 1 of the following regimens:
- Letrozole
- Tamoxifen
- Letrozole after 2 years of tamoxifen
- Tamoxifen after 2 years of letrozole
- Not yet completed 5 years of treatment
- No breast cancer recurrence or second primary cancer
- No known, symptomatic bone disease, including osteomalacia or osteogenesis imperfecta
- No prior registration to protocol IBCSG-1-98 Bone Mineral Density substudy
Hormone receptor status:
- Estrogen receptor-positive and/or progesterone receptor-positive tumor
PATIENT CHARACTERISTICS:
- Female
- Postmenopausal
- No uncontrolled thyroid or parathyroid disease, Cushing's disease, or other pituitary diseases
- No malabsorption syndrome or clinically relevant vitamin D deficiency
- No patients for whom the bone density determination is impossible
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- More than 1 year since prior and no concurrent anticonvulsants
- More than 6 weeks since prior and no concurrent corticosteroids (at doses > the equivalent of 5 mg/day prednisone) for > 2 weeks total
- No prior or concurrent sodium fluoride (at daily doses ≥ 5 mg/day) for > 1 month
- More than 12 months since prior and no concurrent anabolic steroids
- More than 6 months since prior treatment, either investigational or not, for the prevention of osteoporosis (excluding calcium or cholecalciferol [vitamin D])
- No concurrent raloxifene
- Concurrent therapeutic intervention for osteoporosis comprising bisphosphonates allowed
- Concurrent warfarin allowed provided it is given for ≤ 4 weeks
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Tripler
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: Tamoxifène 2 ans plus létrozole 3 ans
Patients traités par tamoxifène pendant 2 ans puis par létrozole pendant 3 ans.
|
Biomarkers (C-telopeptide, osteocalcin and skeletal alkaline phosphatase) will be assessed in serum.
Mone mineral density measurements of L2-L4 and hip will be performed using DEXA.
Thoracic and lumbar X-ray (T4-L4, lateral projection) will be performed.
|
Expérimental: Tamoxifen for 5 years
Patients treated with tamoxifen for 5 years after randomisation.
|
Biomarkers (C-telopeptide, osteocalcin and skeletal alkaline phosphatase) will be assessed in serum.
Mone mineral density measurements of L2-L4 and hip will be performed using DEXA.
Thoracic and lumbar X-ray (T4-L4, lateral projection) will be performed.
|
Expérimental: Letrozole for 5 years
Patients treated with letrozole for 5 years after randomisation.
|
Biomarkers (C-telopeptide, osteocalcin and skeletal alkaline phosphatase) will be assessed in serum.
Mone mineral density measurements of L2-L4 and hip will be performed using DEXA.
Thoracic and lumbar X-ray (T4-L4, lateral projection) will be performed.
|
Expérimental: Letrozole 2 years plus tamoxifen 3 years
Patients treated with letrozole for 2 years and afterwards with tamoxifen for 3 years.
|
Biomarkers (C-telopeptide, osteocalcin and skeletal alkaline phosphatase) will be assessed in serum.
Mone mineral density measurements of L2-L4 and hip will be performed using DEXA.
Thoracic and lumbar X-ray (T4-L4, lateral projection) will be performed.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
---|---|
Relative percent change of bone mineral density (BMD) form baseline to after 2, 3, 4, or 5 years of treatment on protocol IBCSG-1-98
Délai: 5 years after randomisation to BIG 1-98
|
5 years after randomisation to BIG 1-98
|
Recovery of BMD at 1 year after the completion of treatment on protocol IBCSG-1-98
Délai: 6 years after randomisation to BIG 1-98
|
6 years after randomisation to BIG 1-98
|
Proportion of patients with BMD below the absolute threshold value for osteoporosis
Délai: 5 years after randomisation to BIG 1-98
|
5 years after randomisation to BIG 1-98
|
Relative percent change in markers of bone resorption from baseline to after 2, 3, 4, or 5 years of treatment on protocol IBCSG-1-98
Délai: 5 years after randomisation to BIG 1-98
|
5 years after randomisation to BIG 1-98
|
Recovery of the markers of bone resorption at 1 year after the completion of treatment on protocol IBCSG-1-98
Délai: 6 years after randomisation to BIG 1-98
|
6 years after randomisation to BIG 1-98
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chaise d'étude: Stefan Aebi, MD, University Hospital Inselspital, Berne
- Chaise d'étude: Andrea Decensi, MD, European Institute of Oncology
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- CDR0000482381
- NOVARTIS-2026703019 (Autre identifiant: Novartis)
- IBCSG-18-98-BS (Autre identifiant: IBCSG)
- EU-20623 (Autre identifiant: EU)
- IBCSG-1-98-BS (Autre identifiant: IBCSG)
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Cancer du sein
-
AstraZenecaRecrutementAdv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian CancerEspagne, États-Unis, Belgique, Royaume-Uni, France, Hongrie, Canada, Corée, République de, Australie
Essais cliniques sur laboratory biomarker analysis
-
Central and North West London NHS Foundation TrustBritish HIV Association (BHIVA)Pas encore de recrutement